MARBOCYL BOLUS 50 MG TABLET
Država: Irska
Jezik: engleski
Izvor: HPRA (Health Products Regulatory Authority)
Svojstava lijeka
(SPC)
04-11-2016
Neki dokumenti za ovaj proizvod trenutno nisu dostupni, možete poslati zahtjev u našu korisničku službu i mi ćemo vas obavijestiti čim ih budemo mogli dobiti.
Pošalji zahtjev.
Pošalji zahtjev.
Aktivni sastojci:
MARBOFLOXACIN
Dostupno od:
Vetoquinol Ireland Limited
ATC koda:
QJ01MA93
INN (International ime):
MARBOFLOXACIN
Doziranje:
50 Milligram
Farmaceutski oblik:
Bolus
Tip recepta:
POM
Terapijska grupa:
Bovine
Područje terapije:
Marbofloxacin
Terapijske indikacije:
Antibacterial
Status autorizacije:
Authorised
Datum autorizacije:
1999-08-23
Svojstava lijeka
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Marbocyl Bolus 50 mg Tablet
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
3 PHARMACEUTICAL FORM
Tablet.
Off white bolus shaped convex tablet.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Cattle (neonatal calves).
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Marbocyl bolus is indicated in the treatment of neonatal gastroenteritis caused by _Escherichia coli_, in calves of 25-50 kg.
4.3 CONTRAINDICATIONS
None.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
Do not exceed the recommended duration of treatment (3 days)
Each tablet contains:
ACTIVE SUBSTANCE:
Marbofloxacin
50.00 mg
For a full list of excipients, see section 6.1
HEALTH PRODUCTS REGULATORY AUTHORITY
________________________________________________________________________________________________________________________
_Date Printed 19/10/2016_
_CRN 7023455_
_page number: 1_
4.5 SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
When administration is carried out using an applicator, care should be taken to avoid soft tissue injury.
Official and local antimicrobial policies should be taken into account when the product is used. Fluoroquinolones should be
reserved for the treatment of clinical conditions which have responded poorly, to other classes of antimicrobials.
Whenever possible, fluoroquinolones should only be used based on susceptibility testing. Use of the product deviating
from the instructions given in the SPC may increase the prevalence of bacteria resistant to the fluoroquinolones and may
decrease the effectiveness of treatment with other quinolones due to the potential for cross resistance.
SPECIAL PRECAUTIONS TO BE TAKEN BY THE PERSON ADMINISTERING THE VETERINARY MEDICINAL PRODUCT TO ANIMALS
People with known hypersensitivity to fluoroquinolone
Pročitajte cijeli dokument
